HRP20020429B8 - Polymorphic form of atorvastatin calcium - Google Patents
Polymorphic form of atorvastatin calciumInfo
- Publication number
- HRP20020429B8 HRP20020429B8 HR20020429A HRP20020429A HRP20020429B8 HR P20020429 B8 HRP20020429 B8 HR P20020429B8 HR 20020429 A HR20020429 A HR 20020429A HR P20020429 A HRP20020429 A HR P20020429A HR P20020429 B8 HRP20020429 B8 HR P20020429B8
- Authority
- HR
- Croatia
- Prior art keywords
- atorvastatin calcium
- polymorphic form
- theta
- peak
- hydrate
- Prior art date
Links
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 title abstract 2
- 229960001770 atorvastatin calcium Drugs 0.000 title abstract 2
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16615399P | 1999-11-17 | 1999-11-17 | |
PCT/US2000/031555 WO2001036384A1 (en) | 1999-11-17 | 2000-11-16 | Polymorphic form of atorvastatin calcium |
Publications (3)
Publication Number | Publication Date |
---|---|
HRP20020429A2 HRP20020429A2 (en) | 2004-04-30 |
HRP20020429B1 HRP20020429B1 (en) | 2006-05-31 |
HRP20020429B8 true HRP20020429B8 (en) | 2007-03-31 |
Family
ID=22602039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20020429A HRP20020429B8 (en) | 1999-11-17 | 2002-05-16 | Polymorphic form of atorvastatin calcium |
Country Status (20)
Country | Link |
---|---|
EP (3) | EP1235799B1 (de) |
JP (2) | JP2003514798A (de) |
KR (1) | KR20020063190A (de) |
CN (1) | CN1423634A (de) |
AT (2) | ATE478665T1 (de) |
AU (1) | AU783002B2 (de) |
CA (1) | CA2392096C (de) |
CZ (1) | CZ20021642A3 (de) |
DE (2) | DE60018100T2 (de) |
ES (2) | ES2234699T3 (de) |
HR (1) | HRP20020429B8 (de) |
HU (1) | HUP0203257A3 (de) |
IL (2) | IL149681A0 (de) |
PL (1) | PL355805A1 (de) |
PT (2) | PT1235799E (de) |
SI (2) | SI1535613T1 (de) |
SK (1) | SK286789B6 (de) |
WO (1) | WO2001036384A1 (de) |
YU (1) | YU35802A (de) |
ZA (1) | ZA200203755B (de) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
SK6592003A3 (en) * | 2000-11-03 | 2004-01-08 | Teva Pharma | Atorvastatin hemi-calcium form VII |
IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
MXPA03005879A (es) | 2000-12-27 | 2003-09-10 | Ciba Sc Holding Ag | Formas cristalinas de atorvastatina. |
WO2002057229A1 (en) * | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
GEP20053546B (en) * | 2001-06-29 | 2005-06-10 | Warner Lambert Co | Crystalline Forms of 'R-(R*,R*)!-2-(4- Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-'Phenylamino) Carbonyl!-1H-Pyrrole-1-Heptanoic Acid Calcium Salt (2:1) (Atorvastatin) |
US7074818B2 (en) | 2001-07-30 | 2006-07-11 | Dr. Reddy's Laboratories Limited | Crystalline forms VI and VII of Atorvastatin calcium |
IL159626A0 (en) | 2001-07-30 | 2004-06-01 | Reddys Lab Ltd Dr | Crystalline forms of atorvastatin calcium and processes for the preparation thereof |
UA77990C2 (en) * | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
DE03713610T1 (de) * | 2002-02-15 | 2005-10-20 | Teva Pharma | Neue kristallformen von atorvastatin-hemicalcium und verfahren zu deren herstellung, sowie neue verfahren zur herstellung der formen i, viii und ix von atorvastatin-hemicalcium |
WO2003070665A2 (en) | 2002-02-19 | 2003-08-28 | Teva Pharmaceutical Industries Ltd. | Desolvating solvates of atorvastatin hemi-calcium |
SI1515717T1 (sl) * | 2002-06-13 | 2009-02-28 | Novartis Ag | Kalcijeve soli statinov, izvedenih iz indola |
GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
EP1424324A1 (de) * | 2002-11-28 | 2004-06-02 | Teva Pharmaceutical Industries Limited | Kristalline Form F von Atorvastatin |
CA2508871C (en) * | 2002-11-28 | 2008-09-09 | Teva Pharmaceutical Industries Ltd. | Crystalline form f of atorvastatin hemi-calcium salt |
GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
CA2465693A1 (en) * | 2003-06-12 | 2004-12-12 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
UY28501A1 (es) | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
EP3581564A1 (de) | 2004-05-05 | 2019-12-18 | Pfizer Products Inc. | Diethylaminsalzformen von [r-(r*,r*)]-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrol-1-heptansäure |
WO2006011041A2 (en) | 2004-07-20 | 2006-02-02 | Warner-Lambert Company Llc | Crystalline forms of (r-(r*))-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-hept anoic acid calcium salt (2:1) |
WO2006037125A1 (en) | 2004-09-28 | 2006-04-06 | Teva Pharmaceutical Industries Ltd. | Process for preparing forms of atorvastatin calcium substantially free of impurities |
US20060106230A1 (en) | 2004-10-18 | 2006-05-18 | Michael Pinchasov | Processes for preparing amorphous atorvastatin hemi-calcium |
WO2006046109A1 (en) | 2004-10-28 | 2006-05-04 | Warner-Lambert Company Llc | Process for forming amorphous atorvastatin |
WO2006048894A1 (en) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | Novel crystalline forms of atorvastatin calcium and processes for preparing them. |
AU2005305460B2 (en) | 2004-11-22 | 2011-04-21 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
CA2499047A1 (en) | 2005-03-01 | 2006-09-01 | Apotex Pharmachem Inc. | Process for producing atorvastatin hemicalcium |
AU2006281229A1 (en) | 2005-08-15 | 2007-02-22 | Arrow International Limited | Crystalline and amorphous sodium atorvastatin |
AU2006281237A1 (en) | 2005-08-15 | 2007-02-22 | Arrow International Limited | Crystalline and amorphous sodium atorvastatin |
CA2547216A1 (en) | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
EP1923057A1 (de) | 2005-11-21 | 2008-05-21 | Teva Pharmaceutical Industries Ltd | Pharmazeutische Atorvastatin-Formulierung |
EP1808162A1 (de) | 2005-11-21 | 2007-07-18 | Teva Pharmaceutical Industries Ltd. | Pharmazeutische Formulierung von Atorvastatin |
DK1957452T3 (da) | 2005-11-21 | 2010-07-26 | Warner Lambert Co | Nye former af [R-(R*,R*)]-2-(4-fluorphenyl)-B,B-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyre- magnesium |
US8080672B2 (en) | 2005-12-13 | 2011-12-20 | Teva Pharmaceutical Industries Ltd. | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
EP1810667A1 (de) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmazeutische Zusammensetzung enthaltend amorphes Atorvastatin |
WO2007096903A2 (en) * | 2006-02-22 | 2007-08-30 | Matrix Laboratories Ltd | New crystalline form of atorvastatin hemi-calcium |
WO2008108572A1 (en) * | 2007-03-02 | 2008-09-12 | Dong-A Pharm. Co., Ltd. | Novel crystal forms of pyrrolylheptanoic acid derivatives |
WO2009004374A1 (en) | 2007-06-29 | 2009-01-08 | Generics [Uk] Limited | Process for introduction of hydroxyethoxy side chain in bosentan |
US20100260851A1 (en) * | 2007-07-11 | 2010-10-14 | Actavis Group Ptc Ehf | Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium |
CA2703230A1 (en) | 2007-10-24 | 2009-04-30 | Generics [Uk] Limited | Novel crystalline forms |
JP5683276B2 (ja) | 2008-02-08 | 2015-03-11 | ジェネリクス・[ユーケー]・リミテッド | ボセンタンの製造方法 |
AU2009321375A1 (en) | 2008-11-03 | 2010-06-03 | Generics [Uk] Limited | HPLC method for the analysis of bosentan and related substances and use of these substances as reference standards and markers |
WO2010069593A1 (en) * | 2008-12-19 | 2010-06-24 | Krka, D. D., Novo Mesto | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates |
EP2327682A1 (de) * | 2009-10-29 | 2011-06-01 | KRKA, D.D., Novo Mesto | Verwendung von amphiphilen Verbindungen zur gesteuerten Kristallisation von Statinen und Statin Zwischenprodukte. |
CZ201039A3 (cs) | 2010-01-19 | 2011-07-27 | Zentiva, K. S | Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme |
KR20120011249A (ko) * | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
CN102249978A (zh) * | 2011-06-09 | 2011-11-23 | 浙江金立源药业有限公司 | 阿托伐他汀钙的ky晶型及制备方法 |
CN103483238B (zh) * | 2013-08-20 | 2014-12-31 | 蚌埠丰原医药科技发展有限公司 | 阿托伐他汀钙三水合物的制备方法 |
MA39033A1 (fr) | 2013-11-15 | 2017-11-30 | Akebia Therapeutics Inc | Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl] amino}acétique, compositions et leurs utilisations |
CN104945300B (zh) * | 2015-06-17 | 2017-05-10 | 北京嘉林药业股份有限公司 | 一种ⅰ型阿托伐他汀钙的纯化方法 |
CN105085362B (zh) * | 2015-09-18 | 2018-01-05 | 浙江海森药业有限公司 | 高纯度结晶型阿托伐他汀钙的制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
ATE178794T1 (de) * | 1993-01-19 | 1999-04-15 | Warner Lambert Co | Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren |
WO1997003959A1 (en) * | 1995-07-17 | 1997-02-06 | Warner-Lambert Company | Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
-
2000
- 2000-11-16 CN CN00818409A patent/CN1423634A/zh active Pending
- 2000-11-16 ES ES00978744T patent/ES2234699T3/es not_active Expired - Lifetime
- 2000-11-16 CZ CZ20021642A patent/CZ20021642A3/cs unknown
- 2000-11-16 PT PT00978744T patent/PT1235799E/pt unknown
- 2000-11-16 SI SI200031061T patent/SI1535613T1/sl unknown
- 2000-11-16 PL PL00355805A patent/PL355805A1/xx not_active Application Discontinuation
- 2000-11-16 WO PCT/US2000/031555 patent/WO2001036384A1/en active IP Right Grant
- 2000-11-16 AU AU16173/01A patent/AU783002B2/en not_active Ceased
- 2000-11-16 AT AT04027375T patent/ATE478665T1/de not_active IP Right Cessation
- 2000-11-16 ES ES04027375T patent/ES2349364T3/es not_active Expired - Lifetime
- 2000-11-16 CA CA002392096A patent/CA2392096C/en not_active Expired - Fee Related
- 2000-11-16 EP EP00978744A patent/EP1235799B1/de not_active Expired - Lifetime
- 2000-11-16 YU YU35802A patent/YU35802A/sh unknown
- 2000-11-16 DE DE60018100T patent/DE60018100T2/de not_active Expired - Lifetime
- 2000-11-16 KR KR1020027006304A patent/KR20020063190A/ko not_active Application Discontinuation
- 2000-11-16 SK SK674-2002A patent/SK286789B6/sk not_active IP Right Cessation
- 2000-11-16 JP JP2001538875A patent/JP2003514798A/ja not_active Withdrawn
- 2000-11-16 EP EP04027375A patent/EP1535613B1/de not_active Expired - Lifetime
- 2000-11-16 EP EP10157435A patent/EP2206497A1/de not_active Withdrawn
- 2000-11-16 DE DE60044884T patent/DE60044884D1/de not_active Expired - Lifetime
- 2000-11-16 HU HU0203257A patent/HUP0203257A3/hu unknown
- 2000-11-16 PT PT04027375T patent/PT1535613E/pt unknown
- 2000-11-16 AT AT00978744T patent/ATE288893T1/de not_active IP Right Cessation
- 2000-11-16 IL IL14968100A patent/IL149681A0/xx active IP Right Grant
- 2000-11-16 SI SI200030648T patent/SI1235799T1/xx unknown
-
2002
- 2002-05-10 ZA ZA200203755A patent/ZA200203755B/en unknown
- 2002-05-15 IL IL149681A patent/IL149681A/en unknown
- 2002-05-16 HR HR20020429A patent/HRP20020429B8/xx not_active IP Right Cessation
-
2009
- 2009-02-12 JP JP2009030514A patent/JP2009102439A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20020429B8 (en) | Polymorphic form of atorvastatin calcium | |
NO20032758D0 (no) | Krystallinske former av Atorvastatin | |
DE69316894D1 (de) | Wiederverwendbares endoskopisches, chirurgisches instrument | |
DE60137039D1 (de) | Verschiebung von verschlüssen zur herstellung von windeln | |
DE69918445D1 (de) | Kalziumsalze enthaltende schweisshemmende zusammensetzungen | |
DE69932802D1 (de) | Weiche, saugfähige seidenpapierprodukte | |
DE69907796D1 (de) | Chirurgisches Beutelinstrument | |
ITMI981811A0 (it) | Pinza laparoscopica per sutura | |
BR9915515B1 (pt) | composiÇço curÁvel de multicomponentes. | |
MA27349A1 (fr) | Composition cristalline renfermant de l'escitalopram. | |
DE69826121D1 (de) | Ausgefälltes aragonit kalciumkarbonatpigment zur beschichtung von tiefdruckpapieren | |
NO20030559D0 (no) | Fremgangsmåte for produksjon av papir | |
NO20023549L (no) | Fremgangsmåte for rensing av 1,2-dikloretan | |
ID26829A (id) | Turunan-turunan sulfonamida | |
MXPA03008777A (es) | El uso de escitalopram enantiomericamente puro. | |
NO20040390L (no) | Krystallinske former VI og VII av atorvastatinkalsium. | |
DE60126897D1 (de) | Genaue Farbwiedergabe von Markenzeichenmustern | |
NO20035380D0 (no) | Fremgangsmåte for dannelse av m degree nster | |
NO20023837D0 (no) | Modulering av bendannelse | |
DE60235280D1 (de) | Demodulation von mehrträgerphasenmodulierten signalen | |
DE60002275D1 (de) | System zur Erzeugen von Quadratursignalen | |
ID26665A (id) | Antagonis vla-4 | |
IT1305003B1 (it) | Punte per la perforazione del terreno con caratteristicheperfezionate per la rimozione dei detriti rocciosi prodotti e | |
DE59903675D1 (de) | Schaltungsanordnung zur steuerung von luminanzsignalamplituden | |
DE60032221D1 (de) | Trokarsystem |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
B1PR | Patent granted | ||
B8IS | Corrected front page of an hr-b document | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20081115 Year of fee payment: 9 |
|
PBON | Lapse due to non-payment of renewal fee |
Effective date: 20091117 |